Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.

about

Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

P2860

Q47548498-85927BB0-FB22-4DAE-8D8D-F46602876E98 Q50048248-1DCDDDDC-9B2D-4595-AA0A-B869BDDBF47B

P2860

Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.

Item

http://www.wikidata.org/entity/Q38725387

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Biological Characterization of ...... al Antibody Scaffold in Vitro.

@en

type

Item

label

Biological Characterization of ...... al Antibody Scaffold in Vitro.

@en

prefLabel

Biological Characterization of ...... al Antibody Scaffold in Vitro.

@en

P1476

Biological Characterization of ...... al Antibody Scaffold in Vitro.

@en

P2093

Darcey Clark

http://www.w3.org/2001/XMLSchema#string

Frederick W Jacobsen

http://www.w3.org/2001/XMLSchema#string

Jeanine L Bussiere

http://www.w3.org/2001/XMLSchema#string

Kannan Gunasekaran

http://www.w3.org/2001/XMLSchema#string

Kei Kim

http://www.w3.org/2001/XMLSchema#string

Linda Narhi

http://www.w3.org/2001/XMLSchema#string

Ling Liu

http://www.w3.org/2001/XMLSchema#string

Madeline Fort

http://www.w3.org/2001/XMLSchema#string

Mai Phuong Nguyen

http://www.w3.org/2001/XMLSchema#string

Nancy Everds

http://www.w3.org/2001/XMLSchema#string

P2860

The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy.

Development trends for human monoclonal antibody therapeutics.

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

P304

1876-1883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M116.748707

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

292

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27994063

http://www.w3.org/2001/XMLSchema#string

P932

5290959

http://www.w3.org/2001/XMLSchema#string

Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.

about

P2860

P2860

Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932